Beam Therapeutics Snags $135M In Latest Funding Round
Genetic medicine-focused biotechnology company Beam Therapeutics on Wednesday said its latest funding round brought in $135 million, as the company looks to begin clinical development for its gene-editing programs....To view the full article, register now.
Already a subscriber? Click here to view full article